Jeffrey Berney, MD
Family Medicine · Holdrege, NENPI 1467498170
Payments from drug & device makers
Across 218 payments — averaging $15.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$971
- Novo Nordisk$324
- AstraZeneca$237
- Astellas Pharma US Inc$229
- Amgen$199
- Johnson & Johnson$139
- plus $1K from 32 others
What the payments were for
- Food & beverage$3,31398%
- Education$752%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 83 | $971 |
| Novo Nordisk | 27 | $324 |
| AstraZeneca | 6 | $237 |
| Astellas Pharma US Inc | 9 | $229 |
| Amgen | 17 | $199 |
| Johnson & Johnson | 9 | $139 |
| Abiomed | 1 | $134 |
| Aimmune Therapeutics, Inc. | 2 | $128 |
| Novartis | 8 | $112 |
| Lilly USA, LLC | 7 | $107 |
| Otsuka America Pharmaceutical, Inc. | 5 | $91 |
| Medtronic | 1 | $67 |
| Pfizer | 4 | $56 |
| Abbott | 3 | $54 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $53 |
| Sanofi Pasteur Inc. | 3 | $46 |
| Philips North America LLC | 3 | $44 |
| Bayer | 3 | $43 |
| Boehringer Ingelheim | 2 | $32 |
| Dexcom, Inc. | 2 | $28 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $28 |
| Esperion Therapeutics, Inc. | 1 | $27 |
| GSK | 2 | $24 |
| Boston Scientific | 1 | $20 |
| Corium, LLC | 1 | $17 |
| Forte Bio-pharma LLC | 1 | $16 |
| Roche Diagnostics Corporation | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
| Inspire Medical Systems, Inc. | 1 | $15 |
| Ardelyx, Inc. | 1 | $15 |
| Lundbeck LLC | 1 | $14 |
| Organon | 1 | $13 |
| Alkermes, Inc. | 1 | $13 |
| Corcept Therapeutics | 1 | $13 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
| Acadia Pharmaceuticals Inc | 1 | $12 |
| Ironshore Pharmaceuticals Inc. | 1 | $11 |
| Genentech USA, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,387 in reported general payments places this provider in the 85th percentile of 981 family medicine providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 107 | $122,530 |
| XareltoRivaroxaban | 202 | $99,729 |
| JardianceEmpagliflozin | 149 | $93,022 |
| EliquisApixaban | 282 | $92,680 |
| TrulicityDulaglutide | 43 | $41,757 |
| VraylarCariprazine Hcl | 36 | $35,560 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 45 | $32,860 |
| UbrelvyUbrogepant | 27 | $26,750 |
| MyrbetriqMirabegron | 77 | $25,531 |
| JanuviaSitagliptin Phosphate | 55 | $22,363 |
| LinzessLinaclotide | 40 | $21,734 |
| EntrestoSacubitril/Valsartan | 60 | $20,941 |
| RybelsusSemaglutide | 19 | $18,021 |
| MounjaroTirzepatide | 17 | $17,571 |
| OxycontinOxycodone Hcl | 13 | $17,282 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $324 | $140,551126 claims |
| Johnson & JohnsonXarelto | $139 | $99,729202 claims |
| AbbVieVraylar, Ubrelvy, Linzess, Creon, Fetzima | $971 | $96,395142 claims |
| Boehringer IngelheimJardiance | $32 | $93,022149 claims |
| PfizerEliquis | $56 | $92,680282 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Shingrix, Anoro Ellipta | $24 | $61,965124 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $107 | $59,32860 claims |
| Astellas Pharma US IncMyrbetriq | $229 | $25,53177 claims |
| AstraZenecaFarxiga, Brilinta | $237 | $21,71250 claims |
| NovartisEntresto | $112 | $20,94160 claims |
| BayerKerendia | $43 | $14,47423 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 981 family medicine providers in Nebraska.
Other family medicine in Holdrege
- Brandon EssinkCreighton$92.8M
- Adam BroszGrand Island$60M
- David EnszSouth Sioux City$33.3M
- Allen HuntLincoln$17.2M
- Thomas WolfFremont$8.2M
- William FitzgibbonsElkhorn$7M
- Kenneth BladOmaha$1.6M
- Lorrie McGillPapillion$1.5M
- Ralph HaukeOmaha$657K
- Darin GregoryOmaha$423K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.